Pharmena (PHR) Stock Overview
Engages in the sale of dietary supplements in Poland and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
PHR Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Pharmena S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł3.41 |
| 52 Week High | zł4.32 |
| 52 Week Low | zł2.50 |
| Beta | 0.58 |
| 1 Month Change | -3.13% |
| 3 Month Change | -2.57% |
| 1 Year Change | -3.67% |
| 3 Year Change | -53.92% |
| 5 Year Change | -64.03% |
| Change since IPO | -87.60% |
Recent News & Updates
Recent updates
Shareholder Returns
| PHR | PL Personal Products | PL Market | |
|---|---|---|---|
| 7D | 0.6% | 1.6% | 1.0% |
| 1Y | -3.7% | -26.8% | 25.1% |
Return vs Industry: PHR exceeded the Polish Personal Products industry which returned -29% over the past year.
Return vs Market: PHR underperformed the Polish Market which returned 22.2% over the past year.
Price Volatility
| PHR volatility | |
|---|---|
| PHR Average Weekly Movement | 6.0% |
| Personal Products Industry Average Movement | 5.1% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in PL Market | 10.6% |
| 10% least volatile stocks in PL Market | 3.1% |
Stable Share Price: PHR has not had significant price volatility in the past 3 months compared to the Polish market.
Volatility Over Time: PHR's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 7 | Konrad Palka | www.pharmena.eu |
Pharmena S.A. engages in the sale of dietary supplements in Poland and internationally. It also develops 1-MNA (PHR-701 program), a medical device for use in difficult-to-heal wounds. In addition, the company is involved in research and development of therapeutic applications of 1 MNA as an anti-inflammatory and anti-fibrotic drug; and research and development at pulmonary fibrosis, respiratory tract infections, including viral infections, COVID-19, inflammatory diseases, metabolic diseases and other therapeutic applications.
Pharmena S.A. Fundamentals Summary
| PHR fundamental statistics | |
|---|---|
| Market cap | zł37.98m |
| Earnings (TTM) | -zł2.77m |
| Revenue (TTM) | zł1.58m |
Is PHR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHR income statement (TTM) | |
|---|---|
| Revenue | zł1.58m |
| Cost of Revenue | zł264.00k |
| Gross Profit | zł1.31m |
| Other Expenses | zł4.08m |
| Earnings | -zł2.77m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 28, 2026
| Earnings per share (EPS) | -0.25 |
| Gross Margin | 83.26% |
| Net Profit Margin | -175.59% |
| Debt/Equity Ratio | 0% |
How did PHR perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/20 09:18 |
| End of Day Share Price | 2026/05/20 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pharmena S.A. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Adrian Kowollik | Dr. Kalliwoda Research |
| Adrian Kowollik | East Value Research GmbH |